Cost effectiveness of bone density measurements
Brown, Matthew A., Bradlow, J., & Gray, A. M. (2001) Cost effectiveness of bone density measurements. Post Reproductive Health, 7(3), pp. 130-135.
Objective. To assess the cost-effectiveness of bone density screening programmes for osteoporosis.
Study design. Using published and locally available data regarding fracture rates and treatment costs, the overall costs per fracture prevented, cost per quality of life year (QALY) saved and cost per year of life gained were estimated for different bone density screening and osteoporosis treatment programmes.
Main outcome measures. Cost per fracture prevented, cost per QALY saved, and cost per year of life gained.
Results. In women over the age of 50 years, the costs per fracture prevented of treating all women with hormone replacement therapy, or treating only if osteoporosis is demonstrated on bone density screening were £32,594 or £23,867 respectively. For alendronate therapy for the same groups, the costs were £171,067 and £14,067 respectively. Once the background rate of treatment with alendronate reaches 18%, bone density screening becomes cost-saving. Costs estimates per QALY saved ranged from £1,514 to £39,076 for osteoporosis treatment with alendronate following bone density screening.
Conclusions. For relatively expensive medications such as alendronate, treatment programmes with prior bone density screening are far more cost effective than those without, and in some circumstances become cost-saving. Costs per QALY of life saved and per year of life gained for osteoporosis treatment with prior bone density screening compare favourably with treatment of hypertension and hypercholesterolemia.
Impact and interest:
Citation counts are sourced monthly from and citation databases.
These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.
Citations counts from theindexing service can be viewed at the linked Google Scholar™ search.
|Item Type:||Journal Article|
|Additional Information:||Journal of the British Menopause Society|
|Keywords:||Alendronate, Cost-benefit analysis, Densitometry, Hormone replacement therapy, Osteoporosis, alendronic acid, hormone, adult, aged, article, bone density, controlled study, cost control, cost effectiveness analysis, drug cost, drug efficacy, female, fracture, health care cost, health program, hormone substitution, human, hypercholesterolemia, hypertension, major clinical study, mass screening, outcomes research, population research, population risk, quality adjusted life year|
|Divisions:||Current > QUT Faculties and Divisions > Faculty of Health
Current > Institutes > Institute of Health and Biomedical Innovation
|Deposited On:||27 Oct 2015 02:36|
|Last Modified:||27 Oct 2015 02:36|
Repository Staff Only: item control page